Lowering the triglyceride / high - density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on <font color="blue">progression_1</font> <font color="blue">of_1</font> <font color="blue">coronary_4</font> <font color="blue">atherosclerosis_4</font> <font color="blue">in_4</font> <font color="blue">diabetic_5</font> <font color="blue">patients_5</font> <font color="blue">:_5</font> insights from the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study . 
<br>
<br> OBJECTIVES The purpose of this study was to determine the factors associated with the <font color="blue">favorable_1</font> <font color="blue">effect_1</font> <font color="blue">of_1</font> <font color="blue">pioglitazone_1</font> <font color="blue">on_1</font> <font color="blue">atheroma_1</font> <font color="blue">progression_1</font> <font color="blue">._1</font> 
<br> BACKGROUND <font color="blue">Diabetes_1</font> <font color="blue">mellitus_1</font> is associated with accelerated coronary atheroma progression . <font color="blue">Pioglitazone_1</font> <font color="blue">slowed_1</font> <font color="blue">progression_1</font> <font color="blue">compared_1</font> <font color="blue">with_1</font> <font color="blue">glimepiride_1</font> <font color="blue">in_1</font> <font color="blue">this_1</font> <font color="blue">population_1</font> <font color="blue">._1</font> <font color="blue">
<br>_1</font> METHODS <font color="blue">In_1</font> <font color="blue">all_1</font> <font color="blue">,_1</font> <font color="blue">360_6</font> <font color="blue">diabetic_6</font> <font color="blue">patients_6</font> <font color="blue">with_5</font> <font color="blue">coronary_5</font> <font color="blue">artery_5</font> <font color="blue">disease_5</font> were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study . Coronary atheroma progression was evaluated by serial intravascular ultrasound . The relationship between changes in biochemical parameters , percent atheroma volume , and total atheroma volume was investigated . 
<br> RESULTS <font color="blue">Pioglitazone_1</font> <font color="blue">-_1</font> <font color="blue">treated_1</font> <font color="blue">patients_1</font> demonstrated greater increases in high - density lipoprotein cholesterol ( HDL - C ) and reductions in glycated hemoglobin , triglycerides , and C - reactive protein . Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) , triglyceride / HDL - C ratio ( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in low - density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and apolipoprotein A - I ( r = -0.20 , p = 0.01 ) with glimepiride . Substantial atheroma regression , compared to progression , was associated with greater relative increases in HDL - C ( 14.2% vs. 7.8% , p = 0.04 ) , relative decreases in triglycerides ( -13.3% vs. -1.9% , p = 0.045 ) , triglyceride / HDL - C ratio ( -22.5 vs. -9.9% , p = 0.05 ) , and decrease in glycated hemoglobin ( -0.6% vs. -0.3% , p = 0.01 ) . Multivariable analysis revealed that pioglitazone - induced effects on triglyceride / HDL - C were associated with changes in percent atheroma volume ( p = 0.03 ) and total atheroma volume ( p = 0.02 ) . 
<br> CONCLUSIONS Favorable effects of pioglitazone on the triglyceride / HDL - C ratio correlated with <font color="blue">delayed_1</font> <font color="blue">atheroma_1</font> <font color="blue">progression_1</font> <font color="blue">in_1</font> <font color="blue">diabetic_3</font> <font color="blue">patients_3</font> <font color="blue">._3</font> This finding highlights the potential importance of targeting <font color="blue">atherogenic_1</font> <font color="blue">dyslipidemia_1</font> <font color="blue">in_1</font> <font color="blue">diabetic_4</font> <font color="blue">patients_4</font> <font color="blue">with_4</font> <font color="blue">coronary_4</font> <font color="blue">artery_4</font> <font color="blue">disease_4</font> <font color="blue">._4</font>